A phase II multicentric study in adults with acute myelogenous leukaemia (AML) in first complete remission (CR1) using IV BuCy2 in a once daily Bu regimen targeting a narrow therapeutic window prior t...
A phase II multicentric study in adults with acute myelogenous leukaemia (AML) in first complete remission (CR1) using IV BuCy2 in a once daily Bu regimen targeting a narrow therapeutic window prior t...
A phase II multicentric study in adults with acute myelogenous leukaemia (AML) in first complete remission (CR1) using IV BuCy2 in a once daily Bu regimen targeting a narrow therapeutic window prior t...
Statut
Status :
Terminé
Type d'étude
Phase II
Age Min.
18
Ans
Age Max.
65
Ans
Genre
Tous
Aire thérapeutique :
Oncologie
Maladie :
Leucémie
Traitement :
F60002
Phase :
Phase II
Date de début de l'étude :
17 Mai 2010
End date :
19 Juin 2014
Identifiant de l'essai :
F60002 IN 202 G0
Identifiant EudraCT/CTIS :
2009-016601-42
Envoyer par email